{"disease":{"id":"advanced-non-hematologic-malignancies","name":"advanced non hematologic malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00830869","title":"A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01899053","title":"A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02327169","title":"A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}